Mandate

Vinge advises the Port of Gothenburg in the divestment of their container terminal

October 11, 2011

APM Terminals has acquired Skandia Container Terminal AB and will take over the operation of the container terminal in the Port of Gothenburg. Skandia Container Terminal AB was acquired from Göteborg Port Operation AB, a company controlled by the City of Gothenburg. In connection with the transaction, a concession agreement will be entered into concerning the operation of the terminal and related infrastructure. The acquisition is subject to approval of the relevant competition authorities.The transaction was the last of three in relation to the privatization process of the terminal operations in the Port of Gothenburg. The other two terminals, i.e. the ro/ro- and the car terminal respectively, were sold during 2010 and 2011. The Port of Gothenburg is by far the largest port in the Nordic region and the container terminal handles approximately 800,000 containers per year.

Vinge has advised Göteborg Port Operation AB and the Port of Gothenburg throughout the privatization process. The firm’s team was led by Fredrik Sonander and included Charlotte Forssander and Lisa Askbrink, as well as a number of other co-workers from the practice groups M&A, Shipping, Employment and Pensions, Real Estate and Environment.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024